The missed message on methotrexate
Medical Necessity—What Does it Mean?
Almost every physician in this country has heard this phrase, “denied as not meeting medical necessity for the service performed.” What does this mean? How does a practice document medical necessity? Not knowing the answer to these questions can greatly affect a rheumatology practice’s financial well-being.
A Review of Wegener’s Treatment Data
Clinical trials show changing role of existing treatment and introduction of newer medications
Juvenile Fibromyalgia Emerges from Its Silence
It can be treated, say researchers—but only if diagnosed
For MAS, Early Diagnosis Is Key
Research helps hasten diagnosis and treatment of macrophage activation syndrome
How a Rheumatologist Thinks: Cognition and Diagnostic Errors in Rheumatology
The Institute of Medicine has reported that each year up to 98,000 deaths result from iatrogenic injury and error.1 Autopsy series have suggested a 15% error rate in the practice of medicine. These numbers are surprising and concerning and raise important questions about how we practice medicine. What kind of errors do we make as…
The Most Cost-Effective Diagnosis Is the Correct Diagnosis
Comments on the Medicare decision to eliminate consultation codes
Research Across the Spectrum
NIAMS director highlights innovative research initiatives
Ortho Angle
Where rheumatology and orthopedics meet
Within Our Reach–Funded Research Finds Highly Specific Markers of RA
A study recently published in Arthritis & Rheumatism concluded that anti–peptidyl arginine deiminase type 4 (PAD-4) antibodies are highly specific markers of RA and appear to be useful markers of disease severity. The project studied an important and previously unrecognized immune response in RA—anti–PAD-4, which is one of the major proteins that creates other common autoantigens in RA.
- « Previous Page
- 1
- …
- 17
- 18
- 19
- 20
- 21
- 22
- Next Page »